• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Glaukos Corporation filed SEC Form 8-K: Regulation FD Disclosure

    12/9/24 6:30:13 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care
    Get the next $GKOS alert in real time by email
    0001192448false00011924482024-12-092024-12-09

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    ​

    CURRENT REPORT

    ​

    Pursuant to Section 13 or 15(d) of

    The Securities Exchange Act of 1934

    ​

    Date of Report (Date of earliest event reported): December 9, 2024

    Glaukos Corporation

    (Exact name of registrant as specified in its charter)

    ​

    Delaware

        

    001-37463

        

    33-0945406

    (State or other jurisdiction

    ​

    (Commission

    ​

    (I.R.S. Employer

    of incorporation)

    ​

    File Number)

    ​

    Identification No.)

    ​

    ​

    One Glaukos Way
    Aliso Viejo, California

        

    92656

    ​

    ​

    ​

    (Address of principal executive offices)

     

    (Zip Code)

    ​

    Registrant’s telephone number, including area code: (949) 367-9600

    ​

    Not Applicable

    (Former name or former address, if changed since last report.)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class:

        

    Trading Symbol

        

    Name of each exchange on which registered:

    Common Stock

    ​

    GKOS

    ​

    New York Stock Exchange

    ​

    ​

    ​

    ​

    ​

    Item 7.01. Regulation FD Disclosure.

    In a Current Report on Form 8-K filed with the Securities and Exchange Commission on December 3, 2024, Glaukos Corporation (the “Company”) previously disclosed that on December 2, 2024, it had entered into unwind agreements (the “Capped Call Unwind Agreements”) with certain financial institutions (the “Option Counterparties”) relating to a portion of the capped call transactions that were previously entered into by the Company with such Option Counterparties in connection with the issuance of its 2.75% Convertible Senior Notes due 2027 (the “Notes”) in an aggregate principal amount of $287.5 million. The Capped Call Unwind Agreements relate to a portion of capped call transactions corresponding to fifty percent of the number of shares of the Company’s common stock initially underlying the Notes.

    ​

    Pursuant to the Capped Call Unwind Agreements, the Option Counterparties delivered to the Company approximately $53.2 million, which amount was determined based upon the volume-weighted average price per share of the Company’s common stock during the averaging period from December 3, 2024 through December 5, 2024.

    ​

    ​

    ​

    ​

    ​

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    GLAUKOS CORPORATION
    (Registrant)  

    ​

    ​

     

    By:

     /s/ Alex R. Thurman

     

     

    Name:     Alex R. Thurman

     

     

    Title:       Senior Vice President & Chief Financial Officer

    ​

    Date: December 9, 2024

    ​

    ​

    Get the next $GKOS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GKOS

    DatePrice TargetRatingAnalyst
    10/27/2025$120.00Equal Weight → Overweight
    Wells Fargo
    10/1/2025$103.00Buy
    Goldman
    5/1/2025$86.00Overweight → Equal Weight
    Wells Fargo
    2/19/2025$140.00 → $200.00Neutral → Outperform
    Mizuho
    12/11/2024$132.00 → $162.00Neutral → Buy
    Citigroup
    12/6/2024$182.00Buy
    UBS
    12/2/2024$120.00Equal-Weight → Underweight
    Morgan Stanley
    7/10/2024$132.00Buy → Neutral
    Citigroup
    More analyst ratings

    $GKOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN & CEO Burns Thomas William received a gift of 67,353 shares, exercised 166,000 shares at a strike of $30.92 and gifted 67,353 shares, increasing direct ownership by 63% to 255,621 units (SEC Form 4)

    4 - GLAUKOS Corp (0001192448) (Issuer)

    2/10/26 8:14:18 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Director Stapley Marc exercised 15,000 shares at a strike of $24.69 and sold $1,915,576 worth of shares (15,000 units at $127.71) (SEC Form 4)

    4 - GLAUKOS Corp (0001192448) (Issuer)

    1/26/26 9:21:27 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    PRESIDENT & COO Gilliam Joseph E exercised 10,498 shares at a strike of $55.18 and sold $1,340,380 worth of shares (10,498 units at $127.68) (SEC Form 4)

    4 - GLAUKOS Corp (0001192448) (Issuer)

    1/26/26 9:05:54 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    SEC Filings

    View All

    Glaukos Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - GLAUKOS Corp (0001192448) (Filer)

    2/17/26 4:10:25 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Glaukos Corporation

    SCHEDULE 13G - GLAUKOS Corp (0001192448) (Subject)

    2/11/26 12:55:08 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Glaukos Corporation

    SCHEDULE 13G/A - GLAUKOS Corp (0001192448) (Subject)

    2/10/26 11:17:43 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $GKOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key highlights include: Record net sales of $143.1 million in Q4 2025 increased 36% year-over-year on a reported basis and 34% year-over-year on a constant currency basis. Glaucoma record net sales of $119.2 million in Q4 2025 increased 42% year-over-year. U.S. Glaucoma record net sales of $86.4 million in Q4 2025 increased 53% year-over-year. Net sales of $507.4 million in 2025 increased 32% yea

    2/17/26 4:05:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an NDA labeling supplement allowing for re-administration of iDose® TR using a repeat treatment protocol. The FDA approval is in response to Glaukos' 2025 NDA labeling supplement application, and reflects accumulated clinical evidence supporting the safety and tolerability of repeat use for iDose TR. "We are pleased to announce this important labeling enhancement for iDose TR, which should help expand access for patients who may be

    1/28/26 7:00:00 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17

    Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2025 financial results after the market close on Tuesday, February 17, 2026. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 17, 2026. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.)

    1/20/26 7:00:00 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Glaukos from Equal Weight to Overweight and set a new price target of $120.00

    10/27/25 8:30:13 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Goldman initiated coverage on Glaukos with a new price target

    Goldman initiated coverage of Glaukos with a rating of Buy and set a new price target of $103.00

    10/1/25 8:52:09 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Glaukos from Overweight to Equal Weight and set a new price target of $86.00

    5/1/25 7:44:23 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IDOSE TR issued to GLAUKOS CORP

    Submission status for GLAUKOS CORP's drug IDOSE TR (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

    12/15/23 11:41:09 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    FDA Approval for TRAVOPROST issued to GLAUKOS CORP

    Submission status for GLAUKOS CORP's drug TRAVOPROST (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

    12/14/23 7:41:03 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Glaukos Corporation

    SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

    11/14/24 1:21:45 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

    SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

    2/14/24 3:55:55 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

    SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

    2/13/24 5:41:34 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Leadership Updates

    Live Leadership Updates

    View All

    OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors

    NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through se

    1/4/23 8:00:00 AM ET
    $BLU
    $GKOS
    $INSP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director

    Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that William J. Link, Ph.D., will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos' Board and has served as Chairman since June 2001. In connection with Dr. Link's retirement, the Board has appointed Thomas W. Burns, Glaukos' President and Chief Executive Officer and a director on the Board since 2002, to serve as the company's Chairman of the Board, effective upon Dr. Link's retirement on December 31, 2021. Mr. Burns will continue to serve as th

    12/20/21 4:15:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors

    SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the appointment of Denice Torres and Dr. Leana Wen to its Board of Directors, effective today. With the addition of these two directors, Glaukos’ Board of Directors will be comprised of nine directors, eight of whom are independent. “We are delighted and honored to welcome these highly accomplished professionals to the Glaukos Board. Each of these extraordinary women brings a wealth of relevant experience, perspective, leadership and wis

    3/1/21 4:10:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Financials

    Live finance-specific insights

    View All

    Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key highlights include: Record net sales of $143.1 million in Q4 2025 increased 36% year-over-year on a reported basis and 34% year-over-year on a constant currency basis. Glaucoma record net sales of $119.2 million in Q4 2025 increased 42% year-over-year. U.S. Glaucoma record net sales of $86.4 million in Q4 2025 increased 53% year-over-year. Net sales of $507.4 million in 2025 increased 32% yea

    2/17/26 4:05:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17

    Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2025 financial results after the market close on Tuesday, February 17, 2026. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 17, 2026. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.)

    1/20/26 7:00:00 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2025, and reaffirmed its full year 2026 revenue guidance. Preliminary and unaudited total net sales for the fourth quarter of 2025 are expected to be approximately $143 million, a reported increase of 36% compared to the same period in 2024, consisting of approximately $86 million in U.S. Glaucoma net sales, including iDose® TR net sales of approximately $45 million, approximately $33 million in Inter

    1/13/26 4:05:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care